Trexquant Investment LP Acquires 42,674 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Trexquant Investment LP grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 305.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 56,625 shares of the biopharmaceutical company’s stock after buying an additional 42,674 shares during the period. Regeneron Pharmaceuticals accounts for 0.5% of Trexquant Investment LP’s portfolio, making the stock its 15th biggest position. Trexquant Investment LP owned approximately 0.05% of Regeneron Pharmaceuticals worth $40,336,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in REGN. FSA Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. grew its stake in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares during the period. Avalon Trust Co purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $36,000. Finally, Crowley Wealth Management Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth $36,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.5 %

REGN opened at $634.23 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $618.51 and a 1-year high of $1,211.20. The firm’s 50 day simple moving average is $682.93 and its two-hundred day simple moving average is $791.84. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $69.34 billion, a PE ratio of 16.57, a PEG ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the company posted $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.56%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on REGN. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Bernstein Bank dropped their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Finally, Citigroup dropped their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.